Literature DB >> 27401931

Risk factors for local complications in children with community-acquired pneumonia.

Katarzyna Krenke1, Marta Krawiec1, Grażyna Kraj1, Joanna Peradzynska2, Agnieszka Krauze1, Marek Kulus1.   

Abstract

AIM: The aim of this study was to evaluate the factors that could predict the development of local complications (parapneumonic effusion/pleural empyema, necrotizing pneumonia, and lung abscess) in children with community-acquired pneumonia (CAP).
METHODS: Demographic, clinical, and laboratory data were prospectively collected and compared in children with noncomplicated and complicated CAP.
RESULTS: Two-hundred and three patients aged from 2 months to 17 years were enrolled. There were 141 and 62 children with noncomplicated and complicated CAP, respectively. Significantly longer duration of fever and a higher level of acute phase reactants were demonstrated in complicated when noncomplicated to complicated CAP. Asymmetric chest pain as well as prehospital treatment with ibuprofen and acetaminophen were significantly more common in patients with complicated CAP (P < .001, P = .02 and P = .003, respectively). Preadmission cumulative dose of ibuprofen exceeding 78.3 mg/kg (median dose for the entire group) was associated with 2.5-fold higher odds ratio (OR) for CAP complications [OR 2.54 CI (1.31-4.94); P = .008)]. In contrast, pneumococcal vaccination was associated with lower odds ratio [OR.03 CI (.23-.89); P = .03] for local complications.
CONCLUSIONS: Some clinical and laboratory data including chest pain, longer duration of fever, higher acute phase reactants, and especially preadmission treatment with ibuprofen or acetaminophen were associated with local complications of CAP. The results of this study highlight the association between the dose of ibuprofen and local CAP complications.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  children; ibuprofen; parapneumonic effusion; pleural empyema; pneumonia

Mesh:

Year:  2016        PMID: 27401931     DOI: 10.1111/crj.12524

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  8 in total

Review 1.  Infectious pleural effusion status and treatment progress.

Authors:  Wei Yang; Bo Zhang; Ze-Ming Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Necrotizing pneumonia: an emerging problem in children?

Authors:  I Brent Masters; Alan F Isles; Keith Grimwood
Journal:  Pneumonia (Nathan)       Date:  2017-07-25

Review 3.  Serious infectious events and ibuprofen administration in pediatrics: a narrative review in the era of COVID-19 pandemic.

Authors:  Lucia Quaglietta; Massimo Martinelli; Annamaria Staiano
Journal:  Ital J Pediatr       Date:  2021-01-29       Impact factor: 2.638

4.  Predicting severe pneumonia in the emergency department: a global study of the Pediatric Emergency Research Networks (PERN)-study protocol.

Authors:  Todd Adam Florin; Daniel Joseph Tancredi; Lilliam Ambroggio; Franz E Babl; Stuart R Dalziel; Michelle Eckerle; Santiago Mintegi; Mark Neuman; Amy C Plint; Nathan Kuppermann
Journal:  BMJ Open       Date:  2020-12-02       Impact factor: 2.692

Review 5.  Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection.

Authors:  Joëlle Micallef; Thomas Soeiro; Annie-Pierre Jonville-Béra
Journal:  Therapie       Date:  2020-05-07       Impact factor: 2.070

6.  No current evidence supporting risk of using Ibuprofen in patients with COVID-19.

Authors:  Paulo Ricardo Martins-Filho; Edmundo Marques do Nascimento-Júnior; Victor Santana Santos
Journal:  Int J Clin Pract       Date:  2020-10       Impact factor: 3.149

7.  Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?

Authors:  Mohit Sodhi; Mahyar Etminan
Journal:  Chest       Date:  2020-03-31       Impact factor: 9.410

8.  Pericardial Affections in Patients with COVID-19: A Possible Cause of Hemodynamic Deterioration.

Authors:  Fábio Fernandes; Felix José Alvarez Ramires; Fábio Danziato Fernandes; Marcus Vinicius Simões; Evandro Tinoco Mesquita; Charles Mady
Journal:  Arq Bras Cardiol       Date:  2020-09       Impact factor: 2.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.